-
-
-
-
-
-
-
Prime Medicine (PRME) PT Lowered to $5 at Guggenheim
-
-
-
-
-
-
-
Eli Lilly and Verve's gene-editing M&A deal 'an important milestone' - Citizens JMP
-
-
-
-
-
-
-
Prime Medicine (PRME) Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition
-
-
-
-
-
-
-
TD Cowen: '10 Potential "Thome Run" Catalysts to Watch in 2025'
-
-
-
-
-
-
-
Prime Medicine (PRME) to Highlight New Preclinical Data, Including In Vivo Data in Wilson’s Disease, at Upcoming Scientific Meetings
-
-
-
-
-
-
-
Prime Medicine (PRME) Unveils Strategically Focused Pipeline
-
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

